RSVPreF3 OA investigational vaccine clinical trials

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

This study is looking at a new vaccine to protect older adults (60+) from RSV, a common chest infection. We want to see how safe it is, if it causes side effects, and how well it helps your body fight off the virus for up to five years.